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Executive	summary	
 
Introduction 
Drug injection generates by far the most serious health problems related to psychoactive drug 
use, such as blood-borne infections (e.g. human immunodeficiency virus (HIV)) or drug 
overdoses. Previous studies suggest that the prevalence and incidence of drug injection could 
be declining in some European countries, especially in western and southern Europe; 
nonetheless, considerable uncertainty remains about the magnitude and geographic extent of 
the phenomenon. A study of drug users recruited in health services, such as drug treatment 
centres, may contribute to a better understanding of the current position. The European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) has been collecting national data 
on drug injection through the treatment demand indicator (TDI) since 2000. The aim of this work 
is to use the data to estimate recent time trends in the drug injection epidemic in Europe, and 
country differences in such trends. 
 
Methods 
Participants were patients admitted for drug treatment from 2000 to 2011 in the countries with 
available data, Members of the European Union in 2013, plus Norway and Turkey (Europe-30 
(1)) who were included in data reported to the EMCDDA as part of the TDI programme. During 
the study period the number of reporting countries increased from 18 in 2000 to 24 in 2005 and 
30 in 2010–11, and the number of reporting centres increased from 3 070 in 2000 to 4 040 in 
2005 and 6 606 in 2010–11. Reporting centre coverage increased in many countries, with no 
clear downward trend in coverage in any country. We analysed the annual aggregated data on 
three indicators related to current drug injectors among first treatment admissions and all 
treatment admissions (absolute number, population rate and a proportion of all drug treatment 
admissions), and a fourth indicator, number per treatment centre, which was only calculated for 
first treatment admissions. In addition, in order to obtain an overview of the trend in the drugs 
more frequently involved in injection, the percentage distribution of patients’ primary drug 
among those who used injection as the usual route of administration of such drug was 
analysed. The definitions of the variables used in the indicators can be found in the TDI 
standard protocol 2.0. 
 
Results 
Current drug injection indicators among people admitted to drug treatment in Europe-30 have 
declined in recent years. Among first treatment admissions the population rate of current drug 
injectors was 2.74/100 000 inhabitants in 2011 compared to 4.03/100 000 inhabitants in 2005; 
the average number per treatment centre was 1.86 in 2011 compared to 3.92 in 2005; and the 
percentage over the total first treatment admissions was 10.1 % in 2011 compared to 17.0 % in 
                                                 
(1) 28 EU Members States + Norway and Turkey 
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2005. The magnitude of the reduction in indicators for all drug treatment admissions was similar 
or higher. Evidence of a statistically significant downward trend in four or more of the seven 
indicators analysed was found in eight countries (Denmark, Ireland, Spain, Croatia, the 
Netherlands, Slovenia, Slovakia and Finland), while evidence of a statistically significant 
downward trend in one to three indicators, with no evidence of a statistically significant upward 
trend in any indicator, was found in nine other countries (Bulgaria, France, Cyprus, 
Luxembourg, Hungary, Austria, Portugal, Sweden and the United Kingdom). Mixed evidence of 
downward or upward trends depending on the indicator, but predominantly a downward trend, 
was found in three countries (Greece, Italy and Latvia). Evidence of a statistically significant 
upward trend in any drug injection indicator, with no evidence of a statistically significant 
downward trend in any indicator, was found in four countries (the Czech Republic, Germany, 
Malta and Turkey). Heroin was the most common primary drug among drug injectors admitted 
to drug treatment in most countries, except in the Czech Republic, Hungary, Sweden and 
Norway, where ‘stimulants’ were the most common, particularly stimulants other than cocaine, 
and in Estonia and Finland, where ‘opioids other than heroin’ were the most common. The 
relative weight of heroin as the primary drug among drug injectors has decreased in some 
countries, while that of stimulants has increased. 
 
Discussion 
Results indicate that current drug injection among people admitted to drug treatment in Europe-
30 has declined in recent years, both in absolute (population rate and average number per 
treatment centre) and relative (percentage over total drug treatment) terms. These findings 
strongly support the impression that injecting drug use in Europe, especially its incidence, has 
followed a downward dynamic in recent years, and are consistent with other indicators (e.g. HIV 
infection related to drug injection, or TDI-based prevalence of current drug injection among first 
heroin treatment admissions) and the few published studies on this issue in Europe. The 
findings also support the idea that, while heroin remains the drug most frequently involved in 
drug injection, the decline in the number of heroin injectors has meant that drug injectors are 
now more likely to be using stimulants than previously. There are still difficulties in estimating 
drug injection trends from the TDI data in European countries, especially in some countries, 
mainly due to limitations in reporting coverage, the quality of data, differences in drug treatment 
policy and other factors, such as increasing retention in treatment. 
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Introduction	
 
Although psychoactive drugs can be administered by many routes (predominantly orally, 
injected, smoked or snorted), drug injection generates by far the most serious health problems, 
such as blood-borne infections (e.g. HIV) or drug overdoses (1–4). A recent meta-analysis 
found that mortality is much higher in people who inject drugs than in their age and sex peers in 
the general population (standardised mortality ratio (SMR): 14.7; 95 % CI: 13.01–16.35) (5, 6). 
Injecting behaviour is a major contributor to the global burden of disease attributable to illicit 
drug use worldwide, in particular opioid use (7). Given the seriousness of these problems, many 
countries have implemented large-scale harm reduction and treatment interventions that have 
proven effective in reducing them; namely, needle exchange programmes, opioid substitution 
programmes, supervised injection facilities and HIV and hepatitis virus therapies (8–11). There 
are also interventions to prevent initiation into injecting drug use, but these have been less 
thoroughly evaluated (12). 
 
Injecting drug use dramatically increased during the 1980s and 1990s in many European 
countries, and this was accompanied by an increase in the number of HIV infections related to 
this behaviour and the number of deaths from acquired immune deficiency syndrome (AIDS) 
and overdose (13–15). Since then, assessing the magnitude of the phenomenon, its 
consequences and its evolution has been an issue of concern and a challenge for European 
public health services. 
 
As injecting drug use is a hidden phenomenon that affects a very small proportion of the 
population, it is very difficult to obtain valid and reliable estimates of prevalence through direct 
methods such as surveys, making it necessary to use indirect statistical methods, such as 
capture–recapture or benchmark multipliers 
(http://www.emcdda.europa.eu/html.cfm/index65519EN.html). In many countries there are no 
estimates of injecting drug use and, when available, estimates show large variations between 
countries. In 2008, for example, data were available for 12 of the 27 countries that constituted 
the European Union (EU) at the time, and the weighted average of estimated prevalence for 
those 12 countries was 0.25 %, with an uncertainty range (weighted averages of lower and 
upper limits of the country estimates) of 0.22–0.30 %, resulting in an estimate of 859 000 
(753 000–1 019 000) drug injectors (13, 14). More often, there are estimates for regional or 
local levels (16–18). 
 
Regarding temporal trends in drug injection in Europe, some studies suggest that in several 
countries the epidemic was already declining by the early 1990s (and even possibly as early as 
the latter half of the 1980s, as in the Netherlands). This phenomenon is related to evidence on 
the occurrence of transitions from injection to other routes (e.g. heroin users giving up injection 
and transitioning to a smoked or snorted use), or even to a decline in the incidence of drug or 
opioid injection, although incidence data from prospective cohorts are scarce (19–29).  
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Furthermore, data at the European level are infrequent. An EMCDDA report published in 2010 
found that only five European countries had data series for the prevalence of drug injection for 
the period 2002–08, and a significant downward trend in the prevalence of injecting drug use 
was found in only one country (the United Kingdom) (13). Furthermore, trends in drug injection 
prevalence series, estimated using indirect methods, have been published for only a few 
European countries, including Spain, Luxembourg and Switzerland (30–32). In this context, the 
study of drug injecting behaviours among subgroups of drug injectors or problem drug users 
recruited in legal or health services or in the community will contribute to a better understanding 
of the phenomenon in Europe.  
 
Drug treatment data are a source of information that, together with other sources, may allow 
estimates of the prevalence of injecting drug use to be obtained, and can themselves be an 
indirect indicator of problem drug use, particularly concerning heroin and injection (as those are 
the drug users most often targeted by treatment policies as the most problematic), and 
consequently contribute to the estimation of time trends in the prevalence and incidence of drug 
injection. Specifically, since 2000 data on drug injection are collected under the TDI, which are 
available for many European countries. Despite limitations (such as differences in availability, 
coverage and use of drug treatment services, poor centre coverage data or missing values), an 
analysis of these data can provide estimates of temporal trends in the incidence and prevalence 
of drug injecting in Europe, in the main drugs involved in drug injecting behaviours, and in 
changes in injecting behaviours among users of specific drugs. It is important to consider the 
different primary drug distribution by country and the trends in people entering treatment by their 
primary drug when making these analyses, as these factors have an influence on the trend of 
drug injection. To this end, findings from this analysis should be examined for their consistency 
with the results from other data sources, such as estimates of the prevalence of injection, 
surveys among drug injectors or heroin users, mortality indicators or changes in the incidence of 
drug injecting observed in cohort studies and available data on needle and syringe exchange 
programmes. This paper focuses on the analysis of TDI data as an important first component of 
an assessment of drug injection at the European level. Previous analysis of the TDI data has 
suggested that in many countries there may be a downward trend in the proportion of drug 
injectors among individuals admitted to drug treatment (13). However, at the time that this 
analysis was carried out no systematic analysis had been performed of the entire treatment 
data series (2000–11) using several indicators to try to control the effect of time changes in 
coverage within countries regarding the number of reporting centres (13,14, 33, 34). 
The aim of this report is to estimate time trends in the drug injection epidemic in Europe, and 
differences in these trends between geographic areas, using data on drug treatment admissions 
reported by 30 European countries to the EMCDDA over a recent 12-year period (2000–11). 
The study used several indicators derived from the TDI to analyse and assess time trends in 
drug injection (see Table 15). 
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Methods	
Participants		
 
Participants were patients admitted to treatment for drug-related problems in countries of the 
European Union-2013 plus Norway and Turkey (Europe-30), reported to EMCDDA during the 
period 2000–11 as part of the TDI. The number of reporting countries increased from 18 in 2000 
to 24 in 2005 and 30 in 2010 (27 with available data for 2011). The number of reporting centres 
increased from 3 070 in 2000 to 4 040 in 2005 and 6 606 in 2010 (4 584 in 2011), with a 
substantial increase in Ireland after the inclusion of data from general practitioners (GPs) in 
2006. However, it should be noted that the coverage of GPs in TDI data is low, since only two 
countries (Ireland and the United Kingdom) report treatment data from GPs.  
 
Among those countries with sufficient information about the number of reporting centres (23 
countries), this number showed a significant increase in 14 countries, and a decrease in three 
countries. The largest increases were observed in Bulgaria, Romania, Ireland and Greece. 
Centre coverage (the proportion of available treatment centres covered by the reporting system) 
is not easy to calculate because the number of available centres in each country was not 
reported to EMCDDA until 2005. Since then there have been data for most of the countries, but 
data are still lacking in some large countries such as the United Kingdom, while validity is 
probably limited in other countries; data on centre coverage are variable and not stable over the 
study period. Taking this into account, we see that in nine countries with data for the entire 
period 2005–11 the number of available centres increased from 465 to 732. In 15 countries with 
data for 2007–11 the number of available centres increased from 1 512 to 1 769. Centre 
coverage increased from 71 % in 2005 to 78 % in 2011 (after excluding Italy, because of its 
change from an exhaustive reporting system to a sampling system in 2008, and Belgium and 
Slovakia because of important inter-annual variations). When looking at the 15 countries with 
data for 2007–11, and after excluding Poland because of changes in the monitoring system 
resulting in large inter-annual variations, coverage increased from 76 % to 83 %. Some 
countries with full or partial coverage data (Bulgaria, France and Lithuania) showed coverage 
below 50 % for some years. Centre coverage increased over the period in Bulgaria, Denmark, 
France, Lithuania Romania, Slovenia, Slovakia, Sweden and Croatia, and it decreased in the 
Czech Republic, Germany, Greece and Latvia. 
 
The number of treatment admissions for Italy in 2008–11 was estimated to account for the 
mentioned change in the reporting system.  
Data	collection	
 
TDI is one of the five key epidemiological indicators that contribute to the overall EMCDDA aim 
of providing objective, reliable and comparable information at the European level concerning 
drugs, drug addiction and their consequences. The objective of the TDI is to collect information 
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in a harmonised and comparable way across all reporting countries on the number and profile of 
people entering drug treatment (clients) during each calendar year. Although the name of the 
indicator is the ‘treatment demand indicator’, it collects information on people entering treatment 
and excludes individuals who came into treatment in a previous year and continue to receive 
treatment in the current year. As people retained in treatment for a long time (e.g. heroin users 
in opioid substitution treatment) are no longer part of the pool of people at risk of starting 
treatment each year, the TDI indicator represents a sub-section of the entire population of drug 
users in need of treatment. It can therefore be considered as an indirect indicator of the 
unobserved level (2) of people that are potentially in need of drug treatment.  
 
Routine, anonymous case-reporting of standardised core data on the number and 
characteristics of problem drug users presenting for treatment are collected nationally and sent 
to the EMCDDA in aggregate form. The TDI provides a uniform structure for reporting on the 
number and characteristics of clients referred to specific drug treatment facilities. The TDI 
collects information on clients at, or close to, their point of entry into treatment facilities for 
problems with one or more drugs. A core dataset of 20 items are collected anonymously about 
each presenting client concerning their socio-demographic characteristics, treatment contact 
details and drug profile. Each national drug treatment monitoring system may include more 
items than those defined in the EMCDDA TDI protocol, according to national and local 
information needs. Also, the categories of the items collected at the national level may be 
different from those requested in the TDI protocol, as far as it is possible to conduct a reliable 
conversion to the TDI categories (35). 
 
The EMCDDA has been implementing the data reporting from the EU Member States since 
2000, and has adopted formal agreements with the Member States to stimulate and facilitate 
data collection and reporting from the national to the European level. Data were reported based 
on the TDI Protocol 2.0 (35), and collected using the FONTE online tool, and mainly cover 
outpatient and inpatient treatment centres (3). In the 10 years following its implementation it has 
proven difficult in most countries to collect information from other types of treatment centres. 
The level of harmonisation is sufficiently good to enable comparability across countries, even 
though caution should be made in data interpretation due to country differences in the drug 
treatment systems and variability in implementing some TDI definitions. 
 
The TDI standard protocol 2.0 provides system requirements, a classification of treatment 
centres, definitions of terms (e.g. treatment, coverage, first treatment demand), case definition, 
a core item list of 20 variables covering treatment contact, socio-demographic characteristics, 
drug use profiles and injecting behaviour, guidelines on methods of data collection, coding, 
                                                 
(2) According to the estimates in the 2015 European Drug Report: Trends and Developments there are 1.3 million opioid 
users in Europe and recent estimates on injecting drugs available in 14 countries range from less than one to more than 
nine cases for 1000 population. 
(3) TDI version 3.0 has now been released and has been used by the European countries since 2013. 
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analysis and reporting of results, and rules for existing national systems, procedures for quality 
control and a consideration of ethical issues (35).  
 
A case is a person who starts treatment for his/her drug use at a treatment centre during the 
calendar year 1 January to 31 December. If a person starts treatment more than once during 
the same year at the same or another centre, only the last treatment in the year is counted. 
Treatment is considered to have started when a client begins formalised face-to-face contact 
with a treatment centre. First treatment is defined as the very first time in his or her life that a 
person starts treatment for drug problems. Drug treatment centres are defined as outpatient, 
inpatient, low-threshold services, general practitioners and prison treatment units. Primary drugs 
are those reported as causing the client the most problems, as defined by the clients 
themselves or by diagnoses based on ICD-10. Use of the primary drug will usually be the main 
reason for asking for treatment. Admissions to treatment for problems related to the use of 
tobacco or alcohol (tobacco or alcohol as the primary drug) are not reported at the European 
level. Secondary drugs (up to four for each client) are those used in addition to the primary 
drug. Alcohol can be reported as a secondary drug. The protocol includes procedures for 
minimising double counting whilst respecting confidentiality. The use of an attributor (initials, 
date of birth and gender) is recommended to minimise multiple counts. 
 
Among other variables, the protocol includes the following: year of treatment, ever previously 
treated, primary drug, usual route of administration of primary drug, and drug injection 
behaviour in the individual’s lifetime and the last 30 days. ‘Previously treated’ refers to whether 
or not a client had been previously admitted to drug treatment other than the current treatment, 
although in some countries it refers to previous treatments for the same primary drug (see Table 
15). 
 
The primary drug, i.e. the drug reported as causing the client the most problems, can be based 
on problems as defined by clients or on short diagnoses based on the ICD-10. The use of this 
drug is generally the main reason for entering treatment. Items are fully specified in the protocol, 
but they do not necessarily have to be collected in exactly the same form as long as each 
Member State can draw these data from within their national systems. National systems 
frequently collect a broad range of additional information considered relevant or important for 
strategic planning and other purposes. 
Data are collected at treatment centre level and collated at regional/country level (35). Through 
FONTE, countries also report annually the number of drug treatment centres that have reported 
data for the reference year. 
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Data	analysis	
 
For this study, analysis focused on drug injection among people starting drug treatment in 
European countries reporting such data to EMCDDA (4). The unit of observation and analysis 
was time period (year) in each country, because no individual data were reported. 
 
Several indicators related to drug injection were considered in order to study the temporal and 
geographic differences in drug injection, specifically:  
 
x The number of current drug injectors admitted to drug treatment (for all drug treatment 
admissions and first drug treatment admissions — people entering drug treatment for 
the first time in their life).  
x The percentage of current drug injectors admitted to drug treatment in relation to the 
total treatment admissions (for all drug treatment admissions and first drug treatment 
admissions). 
x The population rate of current drug injectors admitted to drug treatment per 100 000 of 
the population aged 15 years and over (for all drug treatment admissions and first drug 
treatment admissions). 
x The average number of current drug injectors admitted to drug treatment per treatment 
centre (only for first drug treatment admissions, since this indicator is used to correct 
possible fluctuations in coverage).  
 
The definition of current drug injection was extracted from the TDI standard protocol 2.0 (35). It 
refers to whether a client has injected any drug at least once in the 30 days before treatment 
admission. The reference point for the 30-day period of use is the start of treatment, in other 
words the first face-to-face session. Injection refers to any drug, regardless of whether such 
drugs were primary or secondary. Injection for medical purposes (such as for diabetes) is 
excluded.  
 
The population of the European countries for the denominators of rates was obtained from 
Eurostat (http://epp.eurostat.ec.europa.eu/portal/page/portal/statistics/themes, accessed 14 
January 2014).  
 
Indicators were calculated for each reporting country, Europe-30 and European Union-2013. 
The indicators refer to cases with known values of the variables involved, as reported to 
EMCDDA. The proportion of missing values in Europe-30 in 2011 was 26.8 % for injecting 
behaviour, 8.5 % for primary drug, 12.7 % for main route of administration of primary drug and 
                                                 
(4) The cases reported by Italy in 2004 did not meet TDI definition because they included all persons who were already 
receiving treatment at the beginning of the year (drug treatment prevalence). For this reason they were excluded from 
the analysis 
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8.3 % for treatment status (ever previously treated). In 2005, these proportions were 27.8 %, 
4.1 %, 26.2 % and 13.3 %, respectively. 
 
The analysis focused on the aforementioned indicators (seven in total) to characterise time 
trends within the same country, assuming that coverage, reporting criteria and treatment 
policies had not changed in any significant way during the study period. In this context, each of 
the indicators has strengths and weaknesses. For example, the percentage of current drug 
injectors admitted to drug treatment in relation to the overall treatment admissions is less 
dependent on the evolution of coverage and use of treatment services than the number or rate 
of treatment admission, but instead it depends heavily on the evolution of the number of 
treatment admissions by drugs administered by non-injection routes. Therefore, to capture or 
obtain information on the underlying trends in the incidence and prevalence of injecting drug 
use it is convenient to use several indicators and observe the consistency of the results. 
 
However, to analyse between-country differences, indicators that referred to the percentage of 
current drug injectors admitted to drug treatment in relation to the total treatment admissions 
were the only ones used, because the use of absolute numbers or population rates of current 
drug injectors is not recommended due to differences in the availability, coverage and use of 
drug treatment services, the coverage of the TDI and missing data. Percentages were 
calculated from cases with known values for the corresponding crossing variables. Data from 
2011 were not available for Ireland, Spain and Poland, and hence those of 2010 were used for 
estimations. 
 
Furthermore, to assess which was the main drug involved in drug injection, the percentage 
distribution of the primary drug among patients admitted to drug treatment who used injection as 
the usual route of administration of such drug was obtained. Injection as the usual route of 
administration refers to injection being the most frequent route of administration of the primary 
drug, without explicitly stating a specific reference period. Primary drug categories considered 
here were opioids, cocaine, other stimulants (mainly amphetamines) and other drugs. The 
statistical significance (p<0.05) of monotonic time trends (2000–11) of each aforementioned 
indicator within each geographic area was assessed by calculating Spearman's correlation 
coefficient (rho) between calendar year and the considered indicator. 
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Results	
Number	of	current	drug	injectors	admitted	to	drug	treatment	
 
The number of patients admitted to drug treatment (all drug treatments) who had injected drugs 
in the last 30 days before starting treatment (current drug injectors) in Europe-30 in 2011 was 
49 006. The United Kingdom (33.0 %) accounted for the largest proportion of current drug 
injectors reported in Europe-30 in 2011, followed by Germany (14.0 %), the Czech Republic 
(9.3 %), Italy (7.2 %), France (6.5 %) and Spain (5.1 %). A total of 12 909 current drug injectors 
were admitted to first drug treatment in 2011, with the United Kingdom (34.8 %) accounting for 
the largest proportion of reported cases, followed by the Czech Republic (16.6 %), Italy 
(13.7 %), Greece (6.6 %), Spain (5.7 %) and Germany (5.0 %). 
 
Regarding time trends, the number of current drug injectors among all treatment admissions in 
Europe-30 was 52 842 in 2000; 52 847 in 2005; and 49 006 in 2011. Using the Spearman’s rho, 
a statistically significant downward trend was identified in 10 countries and a significant upward 
trend in five countries (Table 1). The number of current drug injectors among first treatment 
admissions in Europe-30 varied from 5 398 in 2000 to 15 854 in 2005 and 12 909 in 2011. 
  
Using the Spearman’s rho, a statistically significant downward trend was identified in seven 
countries and no significant upward trend was found in any country (Table 2). It is important to 
note that the increase in the period 2000–05 at the European level is explained by the fact that 
countries did not join the monitoring system at the same time, and the incorporation of large 
countries to the system resulted in large increases in the number of treatment admissions.  
Percentage	of	current	drug	injectors	among	people	admitted	to	drug	
treatment	
 
Current injectors in Europe-30 in 2011 represented 15.0 % of all drug treatment admissions, 
and 10.1 % of first drug treatment admissions. Countries with the highest percentage of current 
drug injectors among all drug treatment admissions were: Latvia (78.5 %), Bulgaria (59.5 %), 
Finland (53.9 %), the Czech Republic (52.5 %) and Romania (51.9 %); and countries with the 
lowest percentages were: Malta (4.6 %), Spain (5.1 %), the Netherlands (5.7 %), Denmark 
(6.1 %), Belgium (8.7 %), and Croatia (9.2 %). Meanwhile, countries with the highest 
percentage of current drug injectors among first drug treatment admissions were: Bulgaria 
(75.2 %), Latvia (62.1 %), the Czech Republic (52.8 %), Romania (39.8 %), Estonia (39.5 %), 
Finland (35.8 %) and Greece (32.2 %); and countries with the lowest percentages were: Malta 
(2.4 %), Spain (2.9 %), Denmark (3.1 %), Belgium (3.4 %), France (3.8 %) and Cyprus (5 %). In 
general, both in 2005 and in 2011, the countries with the highest percentages were located in 
northern or eastern Europe (Tables 3–4). 
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The percentage of current drug injectors among all treatment admissions in Europe-30 was 
34.4 % in 2000; 23.4 % in 2005; and 15.0 % in 2011. A statistically significant downward trend 
was identified in 13 countries (Bulgaria, Denmark, Ireland, Greece, Spain, Croatia, Italy, Cyprus, 
Latvia, Luxembourg, Hungary, Slovakia and the United Kingdom), and a significant upward 
trend was seen in Germany. In other countries the trends were stable, or valid data to 
accurately describe trends were unavailable. In 2000–01 the percentage of current drug 
injectors among people admitted to drug treatment was already low (below 20 %) in countries 
like the Netherlands, Belgium, Spain and Sweden (Table 3). Meanwhile, the percentage of 
current drug injectors among first treatment admissions was 22.1 % in 2000; 17.0 % in 2005; 
and 10.1 % in 2011. A statistically significant downward trend was identified in 12 countries 
(Denmark, Ireland, Greece, Spain, Croatia, Italy, Cyprus, Latvia, Austria, Slovenia, Slovakia and 
the United Kingdom) and a significant upward was not identified trend in any country. In 2000–
01 the percentage of current drug injectors among people admitted to their first drug treatment 
was already low (below 20 %) in countries like the Netherlands, Belgium, Spain and Germany 
(Table 4). 
Population	rate	of	current	drug	injectors	admitted	to	drug	treatment	
 
The rate of current drug injectors admitted to drug treatment in Europe-30 in 2011 was 10.14 
per 100 000 of the population aged 15 and over. The countries with the highest rates per 100 
000 were: Malta (203.3), Latvia (57.47), the Czech Republic (49.36), the United Kingdom 
(30.33) and Ireland (26.20); and the countries with the lowest rates were: the Netherlands 
(0.14), Poland (0.93), Portugal (0.94), Turkey (1.37), and Hungary (2.32). Belgium, Denmark, 
Germany, Spain, France, Italy, Romania and Sweden all had rates lower than 10 (Table 5). 
Also, the rate of current drug injectors admitted to their first drug treatment in Europe-30 in 2011 
was 2.74. The countries with the highest rates were: the Czech Republic (23.25), Malta (13.61), 
Greece (8.71), the United Kingdom (8.42) and Latvia (8.20); and the countries with the lowest 
rates were: the Netherlands (0.06), Poland (0.06), Portugal (0.48) and Turkey (0.6100). Other 
countries, such as Belgium, Denmark, Germany, Spain, France, Croatia, Hungary and Finland, 
showed rates below 2 (Table 6). 
 
The rate of current drug injectors admitted to any drug treatment in Europe-30 was 
21.05/100 000 of the population aged 15 and over in 2000; 13.73/100 000 in 2005; and 
10.14/100 000 in 2011. A statistically significant downward trend was identified in 10 countries 
(Denmark, Ireland, Spain, Croatia, Luxembourg, Hungary, the Netherlands, Slovenia, Slovakia 
and Finland) and a significant upward trend in three countries (Germany, Malta and Turkey) 
(Table 5). In terms of current drug injectors admitted to their first drug treatment in Europe-30, 
the population rate was 3.96/100 000 in 2000; 4.03/100 000 in 2005; and 2.74/100 000 in 2011. 
A statistically significant downward trend was identified in eight countries (Denmark, Ireland, 
Spain, the Netherlands, Portugal, Slovenia, Slovakia and Finland) and a significant upward 
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trend in one country (Turkey). Trends in other countries were stable, or valid data to accurately 
describe trends were unavailable (Table 6). 
Average	number	of	current	drug	injectors	admitted	to	first	drug	
treatment	per	centre		
 
The average number of current drug injectors admitted to their first drug treatment per treatment 
centre in Europe-30 was 1.76 in 2000; 3.92 in 2005; and 1.86 in 2011. A statistically significant 
downward trend was identified in 10 countries (Bulgaria, Ireland, Greece, Spain, France, 
Cyprus, the Netherlands, Slovenia, Finland and Sweden) and a significant upward trend in two 
countries (the Czech Republic and Italy). Trends in other countries were stable, or valid data to 
accurately describe trends were unavailable (Table 7). 
Primary	drug	of	clients	who	usually	injected	
 
The primary drug of clients who usually injected was explored using the percentage distribution 
of the primary drug among those who reported injecting as their usual route of administration. In 
Europe-30 in 2011 opioids were the primary drug most commonly used among all drug 
treatment admissions who reported that they usually injected, at 84.4 %, followed by stimulants 
other than cocaine (8.2 %) and cocaine (5.6 %) (Table 8). In two countries, the Czech Republic 
(74.9 %) and Norway (50.9 %), stimulants were the most common primary drugs among those 
reporting they usually injected, although in some other countries they reached percentages over 
20 % (Belgium, Hungary, Slovakia and Sweden) (Table 12). Among first drug treatment 
admissions, the primary drug most commonly reported by those who usually inject was also 
opioids, although stimulants other than cocaine represented a higher percentage (14.5 %) than 
among all treatment admissions (Table 9). In three countries, namely the Czech Republic 
(85.8 %), Hungary (68.6 %) and Sweden (65.8 %), stimulants were the drugs most commonly 
used by those who usually injected, and in some other countries they represented percentages 
over 20 % (Belgium, Spain, Latvia, Hungary, Poland, Slovakia, Finland and Sweden) (Table 
13). Heroin was the most commonly injected opioid in most countries, although other opioids 
were predominant in Finland and Estonia. Moreover, in France and Austria opioids other than 
heroin were commonly used by those reporting that they usually injected (in over 30 % 
treatment admissions). In all countries where stimulants were the primary drug for a substantial 
percentage of those who usually injected, the most commonly used stimulants were stimulants 
other than cocaine (presumably amphetamines or amphetamine-like substances), except in 
Spain where it was cocaine (26 %). Another country where a substantial percentage of those 
usually injecting reported cocaine as the primary drug was Germany (18.6 % of all treatment 
admissions and 16.6 % of first treatment admissions with injection as the main route of 
administration of the primary drug). 
 
Time trends in Europe-30 were unclear, although a statistically significant upward trend has 
been identified in the proportion of those usually injecting who reported ‘other drugs’ as their 
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primary drug among all drug treatment admissions and first drug treatment admissions. 
Nevertheless, injectors of ‘other drugs’ still only accounted for 1.8 % of all those usually injecting 
(Tables 8–9). By country, among all drug treatment admissions, a statistically significant 
downward trend was identified in the proportion of those who usually injected with opioids as 
the primary drug in seven countries (the Czech Republic, Greece, Spain, Hungary, Malta, 
Slovenia and Sweden) and a statistically significant upward trend in one country (Finland) 
(Table 10). Among first drug treatment admissions, statistically significant trends were identified 
in the same aforementioned countries. In other countries the trend was stable or there were 
insufficient data to derive trends (Table 11). Regarding trends in the proportion with stimulants 
as the primary drug, a statistically significant upward trend was identified in nine countries 
(Bulgaria, the Czech Republic, Denmark, Greece, Spain, Hungary, Malta, Slovenia and 
Slovakia) and a statistically significant downward trend in one country (Finland). Among first 
drug treatment admissions, statistically significant trends were identified in the aforementioned 
countries, except Slovakia. The trend was stable in other countries, or there were insufficient 
data to derive trends (Table 12). 
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Discussion	
 
Indicators related to first treatment admissions can provide a window on recent trends in 
injecting drug use, as they are likely to include those in the treated population who started 
injecting more recently. The results of this analysis indicate that injecting drug behaviour among 
people admitted to first drug treatment in Europe-30 has declined in recent years, both in 
absolute terms (the population rate of current drug injectors and the average number of current 
drug injectors per treatment centre; although it should be noted this data can be affected by an 
expansion of TDI to small treatment centres) and in relative terms (current drug injectors as a 
proportion of total clients admitted to drug treatment). The population rate of current drug 
injectors among first drug treatment admissions was 2.74/100 000 in 2011 compared to 
4.03/100 000 in 2005, the average number of current drug injectors per treatment centre was 
1.86 in 2011 compared to 3.92 in 2005 and the percentage of current drug injectors was 10.1 % 
in 2011 compared to 17.0 % in 2005. Similar decreases were seen for clients admitted to any 
drug treatment (first drug treatment admission or subsequent treatment). 
 
By country, evidence of a statistically significant downward trend was found in four or more 
indicators of the seven studied in eight countries (Denmark, Ireland, Spain, Croatia, the 
Netherlands, Slovenia, Slovakia and Finland), while evidence of a statistically significant 
downward trend in one to three indicators, with no evidence of a statistically significant upward 
trend in any indicator, was found in nine other countries (Bulgaria, France, Cyprus, 
Luxembourg, Hungary, Austria, Portugal, Sweden and the United Kingdom). Mixed evidence of 
downward or upward trends depending on the indicator, but predominantly a downward trend, 
was found in three countries (Greece, Italy and Latvia). Evidence of a statistically significant 
upward trend in some drug injection indicators with no evidence of a statistically significant 
downward trend in any indicator was found in four countries (the Czech Republic, Germany, 
Malta and Turkey). Finally, specific temporal trends were not found for any indicator, due to a 
lack of data or other reasons, in five countries (Estonia, Lithuania, Poland, Romania and 
Norway) (Table 14). 
 
While heroin remains the drug most commonly involved in drug injection among treatment 
clients in most countries, data suggest that the involvement of stimulants is increasing in some 
countries. 
 
These findings support the idea that the epidemic of injecting drug use in Europe has followed a 
downward dynamic in recent years. The decline seems to be clearer from 2008–09 in several 
countries, but further analysis is needed to assess recent trends in drug injection. Specifically, 
the incidence of injecting drug use may have begun to decline for some years prior to the study 
period (2000–11), which was probably followed by slower changes in the prevalence of drug 
injecting, particularly opioid injecting. Some studies suggest that in some European countries 
the incidence of injecting drug use may have begun to decline in the 1990s, and even in the 
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1980s, especially in some western European countries such as the Netherlands and Spain (20, 
21, 25, 29, 36). Additionally, the decrease in the number of new HIV diagnoses related to drug 
injection in the European general population in 2000–12 supports the view that a decrease in 
the prevalence of drug injection has occurred, together with a decrease in the risk of HIV 
infection due to the impact of harm reduction services and other factors (37, 38). Moreover, the 
low proportion of young people or people with a short history of drug injection within samples of 
drug injectors recruited for infectious disease surveillance suggests a low rate of recent initiation 
into injecting, except perhaps in some countries in eastern Europe (34). 
 
These reductions in drug injection could be due to the decline in the incidence and prevalence 
of heroin use (22, 33, 36, 39–41) and the change in route of administration of this drug (usually 
from injecting to smoking or snorting) observed in some countries in the 1990s (21, 27, 29, 42). 
These changes in administration route may have been linked to an increase in awareness of the 
risks associated with injection, the effectiveness of treatment and harm reduction interventions, 
particularly methadone treatment, the type of heroin and other drugs available in the market 
(more or less suitable for injection) or other factors (43, 44). 
 
The results of this study suggest that in Europe-30 the most frequently injected drug is still by 
far heroin, although in some countries the most commonly injected drugs are stimulants other 
than cocaine (the Czech Republic, Hungary, Sweden and Norway) or other opioids (Estonia and 
Finland). In addition, the results also suggest that there are important subgroups of cocaine or 
other stimulants injectors in Belgium, Spain, Germany, Latvia, Poland and Slovakia, and of 
injectors of opioids other than heroin in France and Austria. An increase in injection as the route 
of administration of amphetamine has previously been observed in some European regions 
since the 1990s (45–47), as TDI data presented by the EMCDDA in the European Annual 
Reports shows 
(http://www.emcdda.europa.eu/publications/searchresults?action=list&type=PUBLICATIONS&S
ERIES_PUB=w36).  
 
There are still many difficulties in interpreting time trends in relation to the incidence and 
prevalence of drug injection, due to possible changes in reporting coverage (countries, centres, 
patients), availability and drug treatment policy, drug enforcement policies regarding drug use, 
episode selection criteria, procedures to avoid double counting, variable definitions and volume 
and meaning of missing values in drug injection variables. Trends in all indicators, and 
particularly those referring to the number and population rates of current drug injectors admitted 
to drug treatment, may be affected by changes in the aforementioned factors. In recent years 
countries have scaled up and extended treatment options such as opioid substitution treatment, 
which tend to attract and retain drug injectors in treatment for longer periods. This decreases 
the turnover and repeated treatment admissions in consecutive years (15, 33, 48). 
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Estimating the net effect of changes in treatment policies on the number and rate of drug 
injectors is difficult, since increased attraction would tend to increase these indicators, while 
increased retention would tend to decrease them. Moreover, even though data are scarce, 
coverage of the reporting system has probably improved (15, 48), resulting in an increase in the 
number and rate of drug injectors admitted to treatment. 
 
The percentage of current drug injectors admitted to drug treatment in relation to the total 
treatment admissions, and the average number of current drug injectors per treatment centre, 
are expected to be less affected by changes in the coverage of the reporting system than the 
absolute number and the population rate of drug injectors. However, the percentage of current 
drug injectors can be affected by changes in treatment policies tending to attract a higher 
proportion of users of non-injecting drugs (e.g. cannabis users), which would artificially reduce 
the magnitude of this indicator. In turn, the average number of drug injectors per treatment 
centre can be affected by changes in the average size of treatment centres included in the 
reporting system (e.g. if a large number of small treatment centres, such as GPs, join the 
reporting system, this will tend to artificially reduce the magnitude of the indicator under study).  
Taken together, the effect of those factors that have tended to artificially increase the magnitude 
of the indicators in more recent years, particularly regarding the absolute number and 
population rate of current drug injectors is probably counteracted by other factors of opposite 
effect, hence we can cautiously state that the incidence and prevalence of injecting drug use 
appears to have declined in Europe from 2000 to 2011. Moreover, and as already stated, 
several indicators other than treatment admissions also show a descending trend during the 
study period.  
 
Apart from those limitations already mentioned, when interpreting the results it is necessary to 
note that indicators related to all treatment admissions can take more time to reflect changes 
than can the corresponding indicators related to first treatment admissions. 
 
Precautions were taken in the present study to minimise the effect of common confusion factors 
encountered when using drug treatment data to estimate trends in drug injection. Such 
precautions included consultation with national experts or using several indicators, including 
some less affected by system coverage notification. Moreover, we have predominantly focused 
analysis on individual countries in order to minimise the effect on the trends of changes in the 
number of reporting countries. For the same reason, when groups of countries as Europe-30 or 
European Union-2013 are analysed it is advisable to focus only on the 2005–11 period, 
because until 2005 several large countries had not yet joined the reporting system. Before 2005 
the number of reporting countries was small, and global trends could be greatly influenced by 
the progressive entry into the reporting system of large countries such as Germany, the United 
Kingdom or Italy, with different characteristics from those who were already reporting data.  
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Consequently, in the period 2000–05 trend analysis should focus primarily on the individual 
countries (8–10, depending on the indicator) with available data for that period. 
Furthermore, interpretation of TDI information would benefit considerably from a more detailed 
cross-validation with other indicators (e.g. drug-related deaths, emergency room visits) and ad 
hoc studies (e.g. qualitative or quantitative studies on street samples, studies and reports from 
other drug services not covered in TDI data).  
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Tables	
 
Table 1. Number of current drug injectors admitted to drug treatment, by country (Europe-30, 2000–11). 
 
  2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
 Europe-30 (
u*)  52 842 31 722 45 735 37 847 40 330 52 847 53 339 57 476 58 390 59 058 54793 49 006
 
European 
Union- 2013 (u*) 52 842 31 722 45 735 37 847 40 330 52 300 52 850 56 957 57 892 58 457 53623 47 795
      
 EU before 2004 52 308 31 263 41 032 30 745 32 390 45 277 43 108 48 078 47 799 48 327 42696 37 452
 
EU 2004 and 
after (u*) 534 459 4 703 7 102 7 582 7 023 9 742 8 879 10 093 10 130 10 927 10 343
 Belgium 89  156   645 592 456
 Bulgaria   993 1 219 998 942 882 1 056 1 064 776 973
 Czech Republic   4 266 4199 4 271 4 119 4 129 3 818 3 907 3 777 4 073 4 425
 Denmark (
d*) 909 656 595 654 454 503 441 563 541 530 379 287
 Germany (
u*) 992  293 1 562 2 157  2 968 3 568 3 629 5 817 6 683
 Estonia    496 447 536 233
 Ireland (
d*) 1 359 1 240 1 134 1 131 1 012 949 1 015 1 016 1 046 940 943 943
 Greece (
u*) 1 143 1 908 1 806 1 793 1 981 1 810 2 146 1 952 1 771 2 035 2 059 2 104
 Spain (
d*) 8 406 7 110 5 229 4 391 5 911 3 188 3 351 3 285 7 680 2 565 2 434 2 434
 France   1 939 3 334 2 294 3 125 3 390 3 259 3 106
 Croatia (
d*)   2 353 1 929 2 156 1 192 912 665
 Italy 4 233  9 369 6 231 6 548 2 323 6 846 4 654 3 425
 Cyprus   99 211 163 185 216 180 205 187 147
 Latvia (
u*)   385 488 523 428  996 1 023
 Lithuania     
 Luxembourg (
d*) 539  470 238 413 458 538 195 191 215 132 111
 Hungary (
d*)   242 202 232 199 198
 Malta (
u*)   73 236 31 441   831 668 717
 Netherlands (
d*) 383 491 396 283 219 185 126 103 31 35 31 19
 Austria   1 124 1 320 1 341 1 325 1 190 922
 Poland    293 168 304 304
 Portugal     172 84
 Romania   180 201 1 099 1 223 762
 Slovenia (
d*) 534 459 437 624 534 361 321 273 286 368 232 165
 Slovakia (
d*)   1 114 1 111 966 883 816 888 747 821 731
 Finland (
d*) 1 689 1 395 1 585 1 484 1 371 1 310 1 170 1 100 1 036 1 034 665 726
 Sweden 174 1 361 947 1 072 1 236 1 269 1 343 1 380 1 191 1 573 1 723 401
 United Kingdom
 32 392 17 102 28 870 19 406 18 231 21 984 22 289 25 354 23 955 23 565 18 646 15 751 (1) 
 Norway     453 462
 Turkey (
u*)   358 547 489 519 498 601 717 749
 
 
Notes 
(d*) Statistically significant (p<0.05) downward trend by calendar year estimated with Spearman’s rho. 
 
(u*) Statistically significant (p<0.05) upward trend by calendar year estimated with Spearman’s rho. 
(1) United Kingdom data for 2011 cover April 2010–March 2011.  
 
EU before 2004: Belgium, Denmark, Germany, Ireland, Greece, Spain, France, Italy, Luxembourg, Netherlands, Austria, Portugal, 
Finland, Sweden and United Kingdom. 
 
EU 2004 and after: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, 
Slovakia and Slovenia.
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Table 2. Number of current drug injectors admitted to first drug treatment, by country (Europe-30, 2000–11). 
 
 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Europe-30 (u*) 5 398 4 413 5 488 11 959 11 694 15 854 17 380 17 238 13 832 14 891 13 941 12 909
     
European Union-
2013 (u*) 5 398 4 413 5 488 11 959 11 694 15 659 17 223 17 045 13 641 14 631 13 941 12 576
EU before 2004 (u*) 4 346 3 528 2 940 8 918 7 996 12 334 13 579 13 316 9 883 10 934 10 360 9 206
EU 2004 and after (u*) 1 052 885 2 548 3 041 3 587 3 325 3 644 3 729 3 758 3 697 3 581 3 370
Belgium 8  21   112 129 73
Bulgaria   293 400 243 178 192 196 224 177 209
Czech Republic   2 149 1 959 2 236 2 184 2 050 1 964 1 905 1 810 2 053 2 084
Denmark (d*) 149 120 119 296 60 76 58 75 57 49 28 49
Germany   1 011 70 88 712 332 416 590 634
Estonia    129 99 87 64
Ireland 326 301 259 305 214 206 227 241 264 288 240 240
Greece 604 966 812 824 936 888 985 846 786 897 798 827
Spain (d*) 1 797 1 493 1 143 1 019 1 389 798 737 804 820 674 714 714
France   196 413 323 310 317 321 287
Croatia   357 305 283 185 110 69
Italy 949  2 933 3 503 3 164 978 2 345 2 126 1 721
Cyprus   59 76 50 53 92 50 69 42 22
Latvia 821 708 337 154 195 358 461 589 505 218 106 146
Lithuania             
Luxembourg 12    
Hungary   77 81 62 63 73
Malta   29 78 16 165 0 0 73 37 48
Netherlands (d*) 98 177 130 66 50 29 29 38 12 12 15 8
Austria   261 238 242 260 216 158
Poland    41 23 20 20
Portugal (d*)   288 345 313 311 202 71 43
Romania   171 182 558 540 353
Slovenia (d*) 231 177 62 225 237 154 111 86 99 108 56 42
Slovakia (d*)   322 365 320 269 253 287 268 290 240
Finland (d*) 374 258 346 242 207 204 168 145 120 109 87 79
Sweden 29 213 131 151 163 129 187 186 150 151 161
United Kingdom   5 004 4 907 6 478 6 666 6 231 5 501 5 102 4 864 4 373 (1)
Norway             
Turkey   111 195 157 193 191 260 333
 
Notes 
(d*) Statistically significant (p<0.05) downward trend by calendar year estimated with Spearman’s rho. 
(u*) Statistically significant (p<0.05) upward trend by calendar year estimated with Spearman’s rho. 
(1) United Kingdom data for 2011 cover April 2010–March 2011. 
EU before 2004: Belgium, Denmark, Germany, Ireland, Greece, Spain, France, Italy, Luxembourg, Netherlands, Austria, Portugal, Finland, 
Sweden and United Kingdom. 
EU 2004 and after: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and 
Slovenia. 
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 Table 3. Percentage of current drug injectors admitted to drug treatment, by country (Europe-30, 2000–11). 
 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Europe-30 (d*) 34.4 30.8 34.4 27.6 25.9 23.4 22.1 20.9 21.2 18.5 16.6 15.0
 
European Union-
2013 (d*) 34.4 30.8 34.4 27.6 25.9 23.4 22.1 20.9 21.1 18.5 16.4 14.8
EU 2004 and 
after (d*) 56.4 42.0 48.8 54.3 49.0 49.8 49.0 36.4 37.6 35.7 35.6 32.8
Belgium 15.1     3.7    8.9 8.6 8.7
Bulgaria (d*)    78.0 71.4 74.7 74.2 69.0 61.3 62.9 59.1 59.5
Czech Republic   51.8 53.5 52.2 54.6 55.4 55.8 53.9 51.3 53.3 52.5
Denmark (d*) 51.9 31.8 23.5 19.2 15.5 14.9 13.0 14.5 13.3 11.2 7.5 6.1
Germany (u*) 6.3   2.9 13.4 11.3 11.3 18.9 16.8 15.5 16.0 14.8
Estonia         84.6 67.8 83.4 45.4
Ireland (d*) 30.6 27.8 25.2 23.6 24.8 21.6 20.4 18.6 17.2 13.7 11.8 11.8
Greece (d*) 59.0 52.3 50.3 49.8 47.2 43.2 44.7 41.1 38.1 37.1 36.6 36.2
Spain (d*) 19.6 17.0 14.7 11.6 11.8 8.1 7.5 7.2 16.0 5.6 5.1 5.1
France      12.8 12.6 10.1 11.6 11.5 11.7 11.0
Croatia (d*)       33.0 27.1 30.2 16.1 12.6 9.2
Italy (d*) 73.1    35.2 27.2 20.9 19.0 23.3 16.7 12.4
Cyprus (d*)    50.5 49.3 39.5 35.3 30.2 30.5 31.0 24.8 15.0
Latvia (d*)      100.0 100.0 94.9 90.3 90.3 81.2 78.5
Lithuania             
Luxembourg (d*) 86.4 86.4 78.3 79.3 80.2 82.2 87.8 75.3 70.2 68.5 65.3 49.8
Hungary (d*)        6.4 6.8 5.7 4.8 4.6
Malta    23.0 40.8 68.5   66.6 36.6 38.7
Netherlands 8.1 8.7 7.1 5.4 4.6 4.2 3.7 2.7 6.8 7.4 7.2 5.7
Austria       23.6 25.9 27.7 24.8 25.3 23.7
Poland         15.0 12.3 23.5 23.5
Portugal           17.4 13.1
Romania        10.7 11.8 78.4 68.9 51.9
Slovenia 56.4 42.0 31.3 40.8 47.4 53.0 50.6 41.3 47.6 41.7 30.2 32.0
Slovakia (d*)    57.9 53.2 51.9 50.3 46.4 47.8 46.1 40.7 36.5
Finland 53.3 52.0 51.7 52.2 51.4 52.5 54.1 55.7 58.2 59.7 51.1 53.9
Sweden 26.0 40.8 36.4 36.5 32.6 20.5 21.5 24.1 21.8 28.8 30.2 37.3
United Kingdom (d*) 46.1 44.7 44.4 36.7 33.7 27.6 23.5 24.8 21.5 19.3 15.9 14.2 (1)
Norway           44.8 43.6
Turkey     27.6 27.8 18.1 22.2 24.9 24.3 28.0 37.0
 
Notes 
(d*) Statistically significant (p<0.05) downward trend by calendar year estimated with Spearman’s rho. 
(u*) Statistically significant (p<0.05) upward trend by calendar year estimated with Spearman’s rho. 
(1) United Kingdom data for 2011 cover April 2010–March 2011. 
EU before 2004: Belgium, Denmark, Germany, Ireland, Greece, Spain, France, Italy, Luxembourg, Netherlands, Austria, Portugal, Finland, 
Sweden and United Kingdom. 
EU 2004 and after: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and 
Slovenia. 
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Table 4. Percentage of current drug injectors admitted to first drug treatment, by country (Europe-30, 2000–11). 
 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Europe-30 (d*) 22.1 17.3 19.4 22.0 17.9 17.0 19.3 16.9 15.9 14.7 13.3 10.1
European Union-
2013 (d*) 22.1 17.3 19.4 22.0 17.9 16.9 19.5 16.9 15.9 14.7 13.3 9.9
EU before 2004 (d*) 18.7 14.5 12.7 18.4 13.9 14.4 13.9 12.2 10.5 9.8 8.9 8.0
EU 2004 and 
after (d*) 87.8 79.7 50.4 51.3 47.5 47.2 46.6 33.6 33.7 32.1 31.0 28.9
Belgium   3.8  3.8 4.3 3.4
Bulgaria   67.7 60.3 64.8 66.2 60.4 53.4 65.7 65.3 75.2
Czech Republic   51.3 51.6 52.9 53.8 55.4 55.1 53.6 48.9 54.5 52.8
Denmark (d*) 33.0 15.8 12.3 21.5 5.2 5.9 4.9 5.3 4.0 2.8 1.5 3.1
Germany   57.9 4.2 5.4 5.4 11.6 6.2 6.2 6.6 5.5
Estonia   75.4 63.5 49.7 39.5
Ireland (d*) 17.7 15.2 13.4 14.9 12.2 10.5 10.3 10.1 9.8 8.8 6.7 6.7
Greece (d*) 57.6 48.3 45.8 43.6 43.9 40.4 41.5 38.0 35.6 34.7 32.9 32.2
Spain (d*) 11.8 9.7 8.0 5.8 5.5 3.9 3.5 3.7 3.8 2.9 2.9 2.9
France   5.1 5.6 3.8 4.7 4.1 4.5 3.8
Croatia (d*)   19.8 19.9 19.5 15.1 10.9 6.8
Italy (d*) 81.5  40.9 19.4 24.3 17.5 14.1 14.9 11.9 11.0
Cyprus (d*)   47.6 34.2 24.0 23.9 24.9 18.1 21.7 12.5 5.0
Latvia (d*) 100.0 100.0 100.0 100.0 100.0 100.0 100.0 98.0 94.0 82.6 53.5 62.1
Lithuania     
Luxembourg 57.1    
Hungary   2.9 4.1 2.2 2.2 2.4
Malta   23.4 52.3 5.8 51.4  29.7 12.0 23.9
Netherlands 5.0 7.4 5.3 2.8 2.3 1.5 1.7 1.5 9.2 8.6 12.9 7.1
Austria (d*)   13.7 13.1 13.7 13.0 12.6 10.9
Poland   5.1 4.2 5.7 5.7
Portugal   16.7 17.7 14.8 13.2 9.0 21.1 17.1
Romania   17.4 20.0 69.5 55.8 39.8
Slovenia (d*) 61.3 44.0 11.7 43.4 45.3 46.5 39.6 31.9 40.4 30.4 21.0 20.7
Slovakia (d*)   41.3 38.5 37.1 35.1 31.4 33.3 35.0 29.3 25.8
Finland 40.5 39.7 38.5 37.6 33.4 38.1 39.1 39.2 40.0 38.5 32.5 35.0
Sweden 9.9 19.1 14.9 15.9 13.1 11.0 15.1 15.6 13.5 10.5 11.0 11.0
United Kingdom (d*)   25.3 22.9 19.4 16.0 15.5 13.1 12.3 11.3 9.9 (1)
Norway     
Turkey   20.1 21.8 10.9 14.9 18.3 18.5 31.9
 
Notes 
(d*) Statistically significant (p<0.05) downward trend by calendar year estimated with Spearman’s rho. 
(u*) Statistically significant (p<0.05) upward trend by calendar year estimated with Spearman’s rho. 
(1) United Kingdom data for 2011 cover April 2010–March 2011. 
EU before 2004: Belgium, Denmark, Germany, Ireland, Greece, Spain, France, Italy, Luxembourg, Netherlands, Austria, 
Portugal, Finland, Sweden and United Kingdom.
EU 2004 and after: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, 
Romania, Slovakia and Slovenia. 
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Table 5. Rate of current drug injectors admitted to drug treatment, by country (Europe-30, 2000–11). 
 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Europe-30 (d*) 21.05 25.34 33.81 17.31 20.42 13.73 16.71 15.69 12.87 12.74 11.40 10.14
European Union-
2013 (d*) 21.05 25.34 33.81 17.31 20.42 15.67 19.78 15.55 14.41 14.23 12.68 11.26
EU before 2004 (d*) 20.98 25.32 32.82 15.66 16.40 14.64 18.03 15.40 15.20 14.86 12.73 11.12
EU 2004 and 
after (d*) 32.03 27.38 45.80 31.86 33.89 28.83 34.71 16.39 11.57 11.82 12.49 11.81
Belgium 1.06     1.80    7.22 6.57 4.99
Bulgaria    14.82 18.21 14.92 14.12 13.42 16.17 16.40 12.04 15.22
Czech Republic   49.71 48.79 49.41 47.48 47.31 43.49 44.04 42.21 45.42 49.36
Denmark (d*) 20.90 15.06 13.64 14.96 10.37 11.45 10.00 12.70 12.11 11.77 8.36 6.29
Germany (u*) 1.43   0.42 2.22 3.06 3.05 4.19 5.03 5.12 8.22 9.44
Estonia         43.44 39.27 47.25 20.62
Ireland (d*) 46.08 41.26 36.91 36.12 31.75 29.10 30.33 29.36 29.46 26.71 26.83 26.20
Greece 12.41 20.63 19.42 19.21 21.10 19.18 22.63 20.51 18.53 21.29 21.57 22.16
Spain (d*) 24.66 20.59 14.90 12.27 16.25 8.61 8.91 8.59 19.70 6.51 6.15 6.14
France      3.80 6.47 4.42 5.99 6.47 6.19 5.87
Croatia (d*)       64.79 52.98 59.17 32.70 25.04 18.29
Italy 8.68    18.66 12.35 12.89 4.53 13.26 8.97 6.57
Cyprus    17.55 36.67 27.76 30.84 35.12 28.34 31.24 27.57 21.05
Latvia      20.13 25.63 27.60 22.71 23.03 54.72 57.47
Lithuania             
Luxembourg (d*) 153.34 151.46 130.52 65.41 111.68 122.00 140.63 50.14 48.23 53.10 31.96 26.32
Hungary (d*)        2.83 2.37 2.72 2.33 2.32
Malta (u*)    22.61 72.17 9.35 131.36   239.72 190.45 203.27
Netherlands (d*) 2.96 3.77 3.02 2.15 1.65 1.39 0.94 0.77 0.23 0.26 0.23 0.14
Austria       16.19 18.89 19.05 18.68 16.69 12.86
Poland         0.91 0.52 0.94 0.93
Portugal           1.92 0.94
Romania        1.01 1.15 6.34 7.11 4.45
Slovenia (d*) 32.03 27.38 25.90 36.79 31.32 21.10 18.66 15.79 16.53 21.05 13.18 9.38
Slovakia (d*)    25.32 25.10 21.69 19.72 18.13 19.64 16.44 18.02 16.03
Finland (d*) 39.95 32.86 37.18 34.68 31.89 30.31 26.90 25.14 23.51 23.31 14.90 16.18
Sweden 2.41 18.77 12.99 14.63 16.76 17.08 17.94 18.25 15.59 20.39 22.11 5.11
United Kingdom 68.13 35.74 59.94 40.02 37.33 44.63 44.82 50.51 47.29 46.13 36.21 30.33 (1)
Norway           11.50 11.55
Turkey (u*)     0.71 1.07 0.94 1.00 0.96 1.14 1.34 1.37
(d*) Statistically significant (p<0.05) downward trend by calendar year estimated with Spearman’s rho. 
(u*) Statistically significant (p<0.05) upward trend by calendar year estimated with Spearman’s rho. 
(1) United Kingdom data for 2011 cover April 2010–March 2011. 
EU up to 2004: Belgium, Denmark, Germany, Ireland, Greece, Spain, France, Italy, Luxembourg, Netherlands, Austria, Portugal, 
Finland, Sweden and United Kingdom. 
EU 2004 and after: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, 
Slovakia and Slovenia. 
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Table 6. Rate of current drug injectors admitted to first drug treatment, by country (Europe-30, 2000–11). 
 
 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Europe-30 (d*) 3.96 5.57 6.19 5.43 5.92 4.03 5.30 4.60 2.99 3.14 3.30 2.74
European Union-
2013 (d*) 3.96 5.57 6.19 5.43 5.92 4.58 6.25 4.55 3.33 3.47 3.30 3.02
EU before 2004 3.28 4.66 3.84 4.55 4.05 3.88 5.49 4.15 3.06 3.28 3.09 2.80
EU 2004 and after 29.05 24.44 20.88 12.56 14.76 13.65 12.98 6.88 4.31 4.22 4.09 3.85
Belgium 0.09     0.24    1.25 1.43 0.80
Bulgaria    4.37 5.97 3.63 2.67 2.92 3.00 3.45 2.75 3.27
Czech Republic   25.04 22.76 25.87 25.17 23.49 22.37 21.47 20.23 22.89 23.25
Denmark (d*) 3.43 2.76 2.73 6.77 1.37 1.73 1.31 1.69 1.28 1.09 0.62 1.07
Germany    1.44 0.10 0.12 0.12 1.00 0.47 0.59 0.83 0.90
Estonia         11.30 8.70 7.67 5.66
Ireland (d*) 11.05 10.02 8.43 9.74 6.71 6.32 6.78 6.96 7.44 8.18 6.83 6.67
Greece 6.56 10.45 8.73 8.83 9.97 9.41 10.39 8.89 8.22 9.38 8.36 8.71
Spain (d*) 5.27 4.32 3.26 2.85 3.82 2.15 1.96 2.10 2.10 1.71 1.81 1.80
France      0.38 0.80 0.62 0.59 0.60 0.61 0.54
Croatia       9.83 8.38 7.77 5.07 3.02 1.90
Italy 1.95    5.84 6.94 6.23 1.91 4.54 4.10 3.30
Cyprus    10.46 13.21 8.52 8.83 14.96 7.87 10.51 6.19 3.15
Latvia 42.02 36.41 17.43 7.98 10.14 18.71 24.21 31.08 26.79 11.73 5.82 8.20
Lithuania             
Luxembourg 3.41            
Hungary        0.90 0.95 0.73 0.74 0.86
Malta    8.98 23.85 4.83 49.15   21.06 10.55 13.61
Netherlands (d*) 0.76 1.36 0.99 0.50 0.38 0.22 0.22 0.28 0.09 0.09 0.11 0.06
Austria       3.76 3.41 3.44 3.67 3.03 2.20
Poland         0.13 0.07 0.06 0.06
Portugal (d*)      3.27 3.90 3.53 3.49 2.26 0.79 0.48
Romania        0.96 1.04 3.22 3.14 2.06
Slovenia (d*) 13.85 10.56 3.67 13.27 13.90 9.00 6.45 4.97 5.72 6.18 3.18 2.39
Slovakia (d*)    7.32 8.24 7.19 6.01 5.62 6.35 5.90 6.37 5.26
Finland (d*) 8.85 6.08 8.12 5.66 4.81 4.72 3.86 3.31 2.72 2.46 1.95 1.76
Sweden 0.40 2.94 1.80 2.06 2.21 1.74 2.50 2.46 1.96 1.96 2.07 2.05
United Kingdom    10.32 10.05 13.15 13.40 12.41 10.86 9.99 9.45 8.42 (1)
Norway             
Turkey (u*)     0.22 0.38 0.30 0.37 0.37 0.49 0.61
 
(d*) Statistically significant (p<0.05) downward trend by calendar year estimated with Spearman’s rho. 
(u*) Statistically significant (p<0.05) upward trend by calendar year estimated with Spearman’s rho. 
(1) United Kingdom data for 2011 cover April 2010–March 2011. 
EU before 2004: Belgium, Denmark, Germany, Ireland, Greece, Spain, France, Italy, Luxembourg, Netherlands, Austria, 
Portugal, Finland, Sweden and United Kingdom.
EU 2004 and after: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, 
Romania, Slovakia and Slovenia. 
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Table 7. Average number of current drug injectors admitted to first drug treatment per treatment centre, by country 
(Europe-30, 2000–11. 
 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Europe-30 1.76 1.38 1.54 3.20 3.52 3.92 2.65 2.36 2.19 2.95 2.11 1.86
European Union-
2013  1.76 1.38 1.54 3.20 3.53 3.89 2.64 2.34 2.17 2.90 2.17 1.90
EU before 2004 2.29 1.72 1.31 3.81 4.43 4.27 2.78 2.11 1.88 2.75 1.85 1.69
EU 2004 and 
after (u*) 0.90 0.77 1.95 2.17 2.38 2.91 2.21 3.81 3.63 3.44 4.30 2.89
Belgium      0.40    0.31 1.26 0.60
Bulgaria (d*)    22.54 20.00 12.15 10.47 11.29 8.91 7.23 5.71 3.48
Czech Republic (u*)   7.33 6.78 8.04 8.63 8.37 8.61 8.32 8.34 9.59 10.17
Denmark        0.42 0.32 0.30 0.21 0.38
Germany    1.43 0.07 0.10 0.10 0.79 0.36 0.36 0.48 0.45
Estonia         11.73 9.00 6.69 4.92
Ireland (d*) 2.33 2.23 1.82 1.97 1.59 1.10 0.59 0.58 0.53 0.54 0.44 0.44
Greece (d*) 50.33 37.15 27.07 22.89 21.27 17.76 18.24 15.96 14.83 13.39 10.64 10.09
Spain (d*) 3.65 3.03 2.30   1.61 1.48 1.59 1.63 1.33 1.41 1.41
France (d*)      2.09 2.91 2.38 1.89 1.60 1.89 1.51
Croatia       12.31 5.98 5.15 3.30 2.00 1.25
Italy (u*) 1.85    5.91 6.82 6.13 8.89 17.90 11.25 18.91
Cyprus (d*)    6.56 5.43 3.57 3.53 5.41 3.33 3.45 2.21 1.05
Latvia 25.66 22.13 10.53 4.81 6.09 9.18 11.24 13.70 11.74 6.41 3.12 4.29
Lithuania             
Luxembourg 0.92            
Hungary        0.77 0.87 0.75 0.77 0.86
Malta    29.00 78.00 3.20 33.00   14.60 7.40 9.60
Netherlands (d*) 0.74 0.95 0.78 0.41 0.31 0.18 0.19 0.25 0.08 0.06 0.07 0.04
Austria       1.84 1.54 0.79 1.68 1.39 1.02
Poland         0.14 0.08 0.91 0.91
Portugal      3.74 4.42 4.01 4.20 2.56 0.90 0.55
Romania        2.80 2.94 7.97 7.61 4.53
Slovenia (d*) 14.44 10.41 3.44 12.50 9.88 9.06 6.94 5.06 5.50 5.68 3.11 2.33
Slovakia    1.13 1.03 2.08 0.73 2.50 2.73 2.09 1.66 0.55
Finland (d*) 3.31 1.84 2.12 1.47 1.25 1.27 1.49 1.45 1.13 1.31 1.12 1.10
Sweden (d*) 0.88 1.63 1.15 1.12 1.06 0.61 0.84 0.78 0.59 0.46 0.56 0.56
United Kingdom       3.97 2.17 2.83 2.63 2.68 2.411
Norway             
Turkey     12.33 17.73 10.47 11.35 11.94 16.25 30.27
 
(d*) Statistically significant (p<0.05) downward trend by calendar year estimated with Spearman’s rho. 
(u*) Statistically significant (p<0.05) upward trend by calendar year estimated with Spearman’s rho. 
(1) United Kingdom data for 2011 cover April 2010–March 2011. 
EU before 2004: Belgium, Denmark, Germany, Ireland, Greece, Spain, France, Italy, Luxembourg, Netherlands, Austria, 
Portugal, Finland, Sweden and United Kingdom.
EU 2004 and after: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, 
Romania, Slovakia and Slovenia. 
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Table 8. Distribution of primary drug among people admitted to drug treatment with injection as main administration 
route of primary drug (%) (European Union and Europe-30, 2000–11). 
 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
European 
Union-2013    
Opioids 92.7 90.0 84.1 82.2 81.5 84.5 85.5 85.4 85.9 75.5 84.0 84.5
Stimulants 6.5 9.0 14.6 16.2 16.2 13.6 12.7 12.7 12.3 23.2 14.1 13.6
Cocaine 3.2 3.4 3.2 6.0 5.6 5.4 5.0 5.2 5.5 4.8 5.6 5.6
Other 
stimulants  3.3 5.6 11.4 10.2 10.6 8.2 7.7 7.5 6.8 18.4 8.5 8.0
Other drugs (u*) 0.8 0.9 1.1 1.6 2.3 1.9 1.8 1.9 1.8 1.3 1.9 1.9
n 49 430 37 565 57 267 66 874 66 522 88 454 95 634 100 064 101 005 109 488 87 252 84 338
Europe-30    
Opioids 92.7 90.0 84.1 82.2 81.5 84.6 85.6 85.5 86.0 75.6 83.9 84.4
Stimulants 6.5 9.1 14.6 16.2 16.2 13.5 12.6 12.6 12.3 23.1 14.2 13.7
Cocaine 3.2 3.4 3.2 6.0 5.6 5.4 4.9 5.2 5.5 4.8 5.6 5.6
Other 
stimulants  3.3 5.6 11.4 10.2 10.6 8.1 7.7 7.4 6.8 18.3 8.6 8.2
Other drugs (u*) 0.8 0.9 1.1 1.6 2.3 1.9 1.8 1.9 1.8 1.3 1.9 1.9
n 49 430 37 565 57 267 66 874 66 522 88 986 96 228 100 588 101 501 110 126 88 359 85 495
EU before 2004    
Opioids 92.6 89.9 89.8 86.3 85.8 88.0 88.3 88.2 88.4 75.9 87.4 89.1
Stimulants 6.5 9.2 8.9 12.0 12.6 10.6 10.4 10.3 10.3 22.6 10.7 9.2
Cocaine 3.2 3.5 3.7 7.2 7.5 6.5 6.3 6.5 6.9 5.6 7.0 7.0
Other 
stimulants  3.3 5.7 5.2 4.8 5.1 4.1 4.1 3.8 3.4 17.0 3.7 2.2
Other drugs (u*) 0.8 0.9 1.1 1.8 1.7 1.4 1.3 1.5 1.4 1.5 2.0 1.7
n 48 712 36 833 48 387 55 777 49 584 72 665 75 156 80 345 79 839 93 476 69 548 66 717
EU_2004 and 
later    
Opioids 99.6 99.0 53.2 61.6 68.5 68.3 75.2 73.9 76.6 73.4 70.7 67.2
Stimulants 0.4 0.0 45.6 37.3 27.3 27.1 21.1 22.5 20.0 26.1 27.4 30.1
Cocaine 0.4 0.7 0.3 0.2 0.2 0.2 0.2 0.1 0.1 0.4 0.4 0.4
Other 
stimulants  0.0 0.0 45.6 37.3 27.3 27.1 21.1 22.5 20.0 26.1 27.4 30.1
Other drugs 0.0 0.3 0.9 1.0 4.1 4.4 3.4 3.5 3.4 0.1 1.6 2.3
n 718 732 8 880 11 097 16 647 15 789 20 478 19 719 21 166 16 012 17 704 17 621
    
 
(d*) Statistically significant (p<0.05) downward trend by calendar year estimated with Spearman’s rho. 
(u*) Statistically significant (p<0.05) upward trend by calendar year estimated with Spearman’s rho. 
EU before 2004: Belgium, Denmark, Germany, Ireland, Greece, Spain, France, Italy, Luxembourg, Netherlands, Austria, 
Portugal, Finland, Sweden and United Kingdom.
EU 2004 and after: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, 
Romania, Slovakia and Slovenia. 
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Table 9. Distribution of primary drug among people admitted to first drug treatment with injection as main administration 
route of primary drug (%) (European Union and Europe-30, 2000–11). 
 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
European Union-
2013             
Opioids 92.7 87.9 64.2 77.5 72.9 82.8 83.1 84.4 84.1 76.1 78.5 79.2
Stimulants 6.8 11.2 35.3 23.5 25.1 16.3 15.9 14.4 14.6 22.2 19.5 19.0
Cocaine 2.3 4.0 4.6 5.6 6.1 4.4 5.6 4.3 3.6 4.6 4.1 4.3
Other 
stimulants  4.5 7.1 30.6 17.9 19.0 11.9 10.2 10.1 11.0 17.6 15.4 14.7
Other drugs (u*) 0.4 0.9 0.6 1.1 2.0 0.9 1.0 1.1 1.2 1.8 2.0 1.8
n 5 363 5 450 7 800 14 184 16 315 24 304 27 050 29 989 24 805 22 620 19 161 19 183
Europe-30      
Opioids 92.7 87.9 64.2 77.5 72.9 82.9 83.2 84.5 84.2 76.4 78.8 79.5
Stimulants 6.8 11.2 35.3 23.5 25.1 16.2 15.8 14.3 14.5 21.9 19.2 18.7
Cocaine 2.3 4.0 4.6 5.6 6.1 4.4 5.6 4.3 3.6 4.5 4.0 4.2
Other 
stimulants  4.5 7.1 30.6 17.9 19.0 11.8 10.2 10.1 10.9 17.3 15.2 14.5
Other drugs (u*) 0.4 0.9 0.6 1.1 2.0 0.9 1.0 1.1 1.2 1.8 2.0 1.8
n 5 363 5 450 7 800 14 184 16 315 24 483 27 231 30 183 24 993 22 916 19 458 19 519
(d*) Statistically significant (p<0.05) downward trend by calendar year estimated with Spearman’s rho. 
(u*) Statistically significant (p<0.05) upward trend by calendar year estimated with Spearman’s rho. 
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Table 10. Percentage of drug treatment admissions with injection as main administration route of primary drug who 
reported opioids as primary drug (Europe-30, 2000–11). 
 
 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 
European Union-
2013 92.7 90.0 84.1 82.2 81.5 84.5 85.5 85.4 85.9 75.5 84.0 84.5 
Europe-30 92.7 90.0 84.1 82.2 81.5 84.6 85.6 85.5 86.0 75.6 83.9 84.4 
Belgium 87.9   71.8 69.9 73.6 79.3 
Bulgaria    99.9 100.0 99.9 100.0 99.6 100.0 99.6 99.5 99.7 
Czech 
Republic (d*)   33.5 32.9 31.5 30.3 31.5 28.4 31.0 29.0 28.2 24.8 
Denmark 99.6 98.4 75.1 94.1 92.9 89.2 93.3 91.1 89.4 89.3 90.6 86.9 
Germany 77.1 77.4 80.4 76.0 78.0 76.1 77.3 74.4 76.7 44.9 77.2 76.9 
Estonia    98.7 97.9 95.8 98.1 
Ireland 99.7 99.5 98.5 97.9 95.8 96.8 98.1 97.9 98.8 98.8 98.8 98.8 
Greece (d*) 99.7 99.6 99.4 99.5 99.4 99.3 99.2 99.6 99.2 97.8 97.7 97.3 
Spain (d*) 95.8 95.2 91.8 91.3 90.7 90.0 89.1 87.5 88.0 85.6 84.8 84.8 
France    90.8 89.5 89.9 89.6 90.5 90.6 89.4 
Croatia    100.0 100.0 100.0 100.0 99.9 100.0 
Italy 99.1   96.1 92.7 96.5 96.2 94.7 95.1 96.0 
Cyprus    100.0 100.0 98.4 97.9 98.5 99.1 99.2 99.6 97.9 
Latvia    83.0 83.7 83.1 83.7 83.7 80.4 79.8 
Lithuania    85.6 85.9 85.7 85.7 85.3    
Luxembourg 94.9  94.5 90.8 88.1 84.7 84.7 86.8 89.6 90.1 93.8 84.8 
Hungary (d*)   89.0 85.6 86.2 87.5 87.8 73.8 75.7 74.5 69.8 49.2 
Malta (d*)    98.2 98.7 97.6 95.9 96.2 94.6 93.9 
Netherlands 87.1 90.9 90.0 86.0 78.9 82.2 84.8 81.9 78.9 83.1 68.0 89.2 
Austria    96.0 97.7 97.5 97.3 97.1 97.1 
Poland    92.9 89.6 94.4 94.4 
Portugal     92.9 94.2 
Romania    99.9 98.4 99.8 99.8 99.9 99.5 78.8 62.7 
Slovenia (d*) 99.6 99.0 99.5 99.5 99.1 98.5 99.4 98.2 98.5 96.1 97.4 96.6 
Slovakia    85.3 74.6 76.7 78.0 78.0 79.0 76.5 71.7 67.7 
Finland (u*) 52.8 53.0 52.5 54.5 59.0 64.0 65.2 70.7 73.2 77.4 73.8 81.1 
Sweden (d*) 48.9 50.4 46.9 49.1 49.0 33.4 35.5 36.9 39.6 37.1 38.1 11.7 
United Kingdom 94.7 95.8 94.9 94.1 94.0 95.0 94.4 92.9 93.1 94.3 95.2 95.2 (1) 
Norway     48.9 39.3 
Turkey    96.9 98.1 99.7 99.2 98.6 99.4 97.6 99.5 
(d*) Statistically significant (p<0.05) downward trend by calendar year estimated with Spearman’s rho. 
(u*) Statistically significant (p<0.05) upward trend by calendar year estimated with Spearman’s rho. 
(1) United Kingdom data for 2011 cover April 2010–March 2011. 
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Table 11. Percentage of first drug treatment admissions with injection as main administration route of primary drug who 
reported opioids as primary drug (Europe-30, 2000–11). 
 
 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 
European Union-
2013 92.7 87.9 64.2 77.5 72.9 82.8 83.1 84.4 84.1 76.1 78.5 79.2 
Europe-30 92.7 87.9 64.2 77.5 72.9 82.9 83.2 84.5 84.2 76.4 78.8 79.5 
Belgium 85.0   70.6 58.1 67.4 77.9 
Bulgaria    100.0 100.0 99.6 100.0 99.6 100.0 98.5 100.0 99.6 
Czech 
Republic (d*)   24.7 23.3 20.9 22.4 22.3 20.6 21.0 20.5 17.8 13.9 
Denmark 98.3 94.9 92.5 93.3 91.7 81.4 93.3 100.0 80.0 66.7 83.3 100.0 
Germany  84.1 85.1 81.7 78.3 81.0 79.2 78.2 79.2 45.6 78.9 79.0 
Estonia    96.5 93.9 89.1 96.5 
Ireland 99.6 99.4 99.1 98.6 99.2 98.3 98.5 99.6 97.8 99.4 98.5 98.5 
Greece (d*) 99.7 99.6 99.4 100.0 99.3 99.6 99.1 99.7 99.6 98.6 99.0 98.4 
Spain (d*) 92.7 92.8 85.2 84.7 84.0 83.1 82.0 78.2 79.0 73.5 73.1 73.1 
France    89.5 87.2 90.7 91.1 90.4 88.8 90.8 
Croatia    99.8 100.0 100.0 100.0 100.0 99.4 
Italy 99.5   92.8 89.0 96.0 96.3 90.5 93.9 94.4 
Cyprus    100.0 100.0 96.6 98.4 100.0 100.0 100.0 97.8 100.0 
Latvia 96.2 95.3 79.8 67.8 55.3 66.3 69.4 71.3 71.4 68.4 73.1 67.7 
Lithuania    84.8 84.2 82.0 76.9 74.2 85.7 82.7 78.2 
Luxembourg 87.5      
Hungary (d*)    75.8 84.0 79.1 53.5 60.2 53.8 41.8 24.8 
Malta (d*)    93.1 98.7 97.1 94.1 0.0 0.0 85.9 93.0 84.5 
Netherlands 80.4 91.6 87.8 75.0 65.6 73.2 82.9 87.8 80.5 80.0 69.2 92.0 
Austria    94.5 98.2 96.7 99.2 95.6 93.6 
Poland    88.2 84.8 75.0 75.0 
Portugal     93.9 97.6 
Romania    100.0 99.4 99.8 99.9 99.7 99.2 83.1 67.9 
Slovenia (d*) 99.6 98.0 100.0 99.6 99.6 99.3 100.0 98.9 99.0 96.7 97.0 97.5 
Slovakia    75.6 62.4 63.3 63.8 69.5 69.5 68.3 62.0 57.6 
Finland (u*) 52.8 50.0 45.5 39.8 41.3 47.6 52.8 61.9 56.6 69.7 71.4 78.3 
Sweden (d*) 38.8 39.9 31.2 33.3 31.2 29.2 29.1 32.6 29.3 33.9 30.3 30.3 
United Kingdom    93.2 91.4 93.3 93.3 90.9 89.2 89.7 92.0 93.3 (1) 
Norway       
Turkey    97.8 97.8 100.0 99.0 97.9 99.3 97.3 99.1 
(d*) Statistically significant (p<0.05) downward trend by calendar year estimated with Spearman’s rho. 
(u*) Statistically significant (p<0.05) upward trend by calendar year estimated with Spearman’s rho. 
(1) United Kingdom data for 2011 cover April 2010–March 2011. 
 36
Table 12. Percentage of drug treatment admissions with injection as main administration route of primary drug who 
reported stimulants as primary drug (Europe-30, 2000–11). 
 
 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 
European Union-
2013 6.5 9.1 14.6 16.2 16.2 13.6 12.7 12.7 12.3 23.2 14.1 13.7 
Europe-30 6.5 9.1 14.6 16.2 16.2 13.5 12.6 12.6 12.3 23.1 14.2 13.7 
Belgium 11.2   28.0 28.9 25.5 20.5 
Bulgaria (u*)    0.1 0.1 0.2 0.2 0.3 
Czech 
Republic (u*)   66.3 66.8 68.4 69.6 68.3 71.5 68.8 70.9 71.8 74.9 
Denmark (u*)  1.4 3.3 5.3 6.5 9.4 6.4 8.9 9.8 9.6 8.2 11.7 
Germany 20.4 19.0 17.5 19.9 19.1 21.4 20.0 21.7 19.9 52.9 18.3 18.6 
Estonia    1.3 1.9 4.2 1.9 
Ireland 0.3 0.4 1.4 2.0 4.1 3.2 1.9 2.1 1.1 1.2 1.0 1.0 
Greece (u*) 0.2 0.3 0.5 0.5 0.4 0.6 0.7 0.3 0.7 2.0 2.0 2.5 
Spain (u*) 3.8 4.7 8.1 8.6 9.1 9.8 10.7 12.4 11.9 14.1 14.9 14.9 
France    6.6 7.9 8.6 9.6 8.3 8.5 9.9 
Croatia    0.1  
Italy 0.8   3.7 6.6 3.5 3.7 5.1 4.6 4.0 
Cyprus    1.6 2.1 1.5 0.9 0.8 0.4 2.1 
Latvia    16.4 16.3 16.6 16.3 16.3 19.3 19.8 
Lithuania    1.7 1.7 1.6 1.7 1.8   
Luxembourg 5.1  5.5 9.2 11.9 15.3 15.3 13.2 10.4 9.9 6.3 15.2 
Hungary (u*)   7.5 10.5 10.5 9.6 10.1 24.3 23.5 24.8 27.2 44.3 
Malta (u*)    1.4 1.3 2.4 4.1 3.8 5.3 6.0 
Netherlands 10.6 8.2 9.0 12.1 15.4 16.2 13.9 15.2 18.0 12.8 29.6 8.8 
Austria    3.7 2.3 2.4 2.3 2.4 2.2 
Poland    6.8 9.7 5.0 5.0 
Portugal    7.1 5.1 
Romania    0.1 0.1 0.4 0.2 
Slovenia (u*) 0.4 0.7 0.5 0.5 0.9 1.5 0.6 1.8 1.5 3.9 2.6 3.4 
Slovakia (u*)    13.8 23.0 21.1 21.9 21.8 21.0 23.5 28.3 32.0 
Finland (d*) 47.0 46.7 47.1 44.5 40.3 35.3 34.4 29.0 26.3 22.2 25.3 18.6 
Sweden 51.1 49.1 52.4 50.3 50.3 54.7 54.9 53.3 59.6 50.1 50.8 33.1 
United Kingdom 4.0 3.3 3.7 4.8 4.9 4.2 4.9 6.0 5.6 4.6 4.1 4.4 (1) 
Norway    44.5 50.9 
Turkey    0.3 0.9 0.2 0.2 0.4 0.7 0.3 
(d*) Statistically significant (p<0.05) downward trend by calendar year estimated with Spearman’s rho. 
(u*) Statistically significant (p<0.05) upward trend by calendar year estimated with Spearman’s rho. 
(1) United Kingdom data for 2011 cover April 2010–March 2011. 
 37
Table 13. Percentage of first drug treatment admissions with injection as main administration route of primary drug who 
reported stimulants as primary drug (Europe-30, 2000–11). 
 
 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 
European Union-
2013 6.8 11.2 35.3 23.5 25.1 18.3 15.9 14.4 14.6 22.2 19.5 19.0 
Europe-30 6.8 11.2 35.3 23.5 25.1 18.2 15.8 14.3 14.5 21.9 19.2 18.7 
Belgium 10.0     29.4    41.1 30.2 20.8 
Bulgaria    0.4 0.4 0.4  0.4 
Czech 
Republic (u*)   75.1 76.3 79.1 77.4 77.6 79.4 78.7 79.5 82.1 85.8 
Denmark (u*)  5.1 6.0 6.7 6.3 11.6 6.7 17.1 25.0 16.7  
Germany (u*)  12.9 13.1 16.5 16.3 15.7 16.7 17.8 16.7 51.7 16.3 16.6 
Estonia         3.5 5.3 10.9 3.5 
Ireland 0.4 0.3 0.6 1.4 0.4 1.7 1.5 0.4 2.2 0.6 1.5 1.5 
Greece (u*) 0.1 0.3 0.5 0.0 0.4 0.4 0.7 0.1 0.4 1.1 0.8 1.6 
Spain (u*) 7.0 6.9 14.7 15.4 16.2 16.9 17.6 21.6 20.5 26.0 25.7 25.7 
France      6.4 8.6 8.5 8.2 8.7 10.4 8.4 
Croatia       0.2  0.6 
Italy 0.4    7.1 10.1 4.0 3.7 9.0 5.8 5.6 
Cyprus    3.4 1.6 2.2  
Latvia 3.2 4.3 19.6 32.2 44.7 32.5 30.6 28.4 28.6 31.6 26.2 31.6 
Lithuania     1.0 3.2 3.1 3.4 2.8 0.7 2.3 1.7 
Luxembourg 12.5            
Hungary (u*)     17.9 12.6 18.3 45.6 38.2 46.2 52.0 68.6 
Malta (u*)    0.9 1.3 2.9 5.9   14.1 7.0 15.5 
Netherlands 12.5 5.6 10.1 22.1 20.0 24.4 14.6 4.9 14.6 10.0 25.0 6.0 
Austria       4.8 1.3 2.9 0.4 3.1 4.5 
Poland         9.8 12.1 25.0 25.0 
Portugal           6.1 2.4 
Romania     0.2 0.2 0.7 0.4 
Slovenia (u*) 0.4 1.0  0.4 0.4 0.7 1.1 1.0 3.3 3.0 2.5 
Slovakia    22.0 34.8 31.8 36.2 30.2 30.5 31.7 38.0 41.6 
Finland (d*) 46.9 49.6 54.3 59.5 57.3 51.5 46.6 38.1 43.4 29.5 26.2 21.7 
Sweden 61.2 58.7 67.8 65.4 67.1 68.2 69.7 64.8 70.1 65.6 65.8 65.8 
UK    5.5 6.6 5.6 6.0 7.3 8.2 6.5 5.8 5.8 (1) 
Norway             
Turkey     1.1 0.6 0.5 0.7 0.3 
 
(d*) Statistically significant (p<0.05) downward trend by calendar year estimated with Spearman’s rho. 
(u*) Statistically significant (p<0.05) upward trend by calendar year estimated with Spearman’s rho. 
(1) United Kingdom data for 2011 cover April 2010–March 2011. 
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Table 14. Summary of time trends in injecting drug use in European countries based on data from the treatment demand indicator 
(Europe-30, 2000–11). 
         
 All drug treatment admissions First drug treatment admissions  
Country 
Indicator 
I Indicator II 
Indicator 
III
Indicator 
I Indicator II Indicator III 
Indicator 
IV Summary
Belgium      
Bulgaria  D  D 2D
Czech Republic    U 1U
Denmark D D D D D D  6D
Germany U U U   3U
Estonia     
Ireland D D D D D D 6D
Greece U D D  D 3D1U
Spain D D D D D D D 7D
France    D 1D
Croatia D D D D   4D
Italy  D D  U 2D1U
Cyprus  D D  D 3D
Latvia U D D   2D1U
Lithuania     
Luxembourg D D D   3D
Hungary D D D   3D
Malta U  U   2U
Netherlands D  D D D D 5D
Austria   D   1D
Poland     
Portugal   D D  2D
Romania     
Slovenia D  D D D D D 6D
Slovakia D D D D D D  6D
Finland D  D D D D 5D
Sweden    D 1D
United Kingdom  D D   2D
Norway     
Turkey U  U U  3U
Nº countries 
with D 10 13 10 7 12 8 10 
Nº countries 
with U 5 1 3 0 0 1 2 
         
Indicator I: Number of current drug injectors admitted to drug 
treatment.     
Indicator II: Percentage of current drug injectors over people admitted to drug 
treatment.    
Indicator III: Rate of current drug injectors admitted to drug treatment per 100 000 population aged 15 and over.  
Indicator IV: Number of current drug injectors admitted to drug treatment per treatment centre.   
D: Statistically significant downward trend estimated with Spearman's rho.    
U: Statistically significant upward trend estimated with Spearman's rho.    
 
 
 
 
 39
Table 15. List of items relevant to an analysis of drug injection. 
 
Item Possible answers Definition 
 
Year of treatment Year… The starting date of treatment is essential for creating 
trend analyses over time and for separating time periods 
(treatment episodes) for reporting. This enables a 
dynamic analysis of the treatment data. 
 
Ever previously 
treated 
1. Never 
2. Previously treated 
0. Not known 
 
This item makes it possible to estimate the incidence of 
cases and client flow through treatment services. The 
category ‘never’ refers to a client who has never received 
treatment for drug misuse at any centre anywhere. He or 
she is thus making a first ever treatment demand. 
‘Previously treated’ refers to a client who has received 
treatment for his/her drug misuse at some point in the 
past, either from the current treatment centre or from 
another treatment centre. 
 
Primary drug Opiates (total) 
11 Heroin 
12 Methadone 
13 Other opiates 
2. Cocaine (total) 
21 Cocaine 
22 Crack 
3. Stimulants (total) 
31 Amphetamines 
32 MDMA and other derivates 
33 Other stimulants 
4. Hypnotics and sedatives (total) 
41 Barbiturates 
42 Benzodiazepines 
43 Others 
5. Hallucinogens (total) 
51 LSD 
52 Others 
6. Volatile inhalants 
7. Cannabis (total) 
9. Other substances (total) 
 
This item is of central importance. The main drug is 
defined as the drug that causes the client the most 
problems. It should be noted that different systems may 
define this category differently. It can be based on 
problems as defined by clients (e.g. NL and UK) or on 
short diagnoses based on the ICD10 (D). As empirical 
research is still lacking on this matter, it remains unclear if 
this really provides sufficient comparability between 
countries. Alcohol must not be recorded as the primary 
drug. Clients whose primary drug is alcohol should be 
excluded from this protocol. For users of ‘speedball’, 
heroin should be recorded as the main drug and cocaine 
as a secondary drug. If the exact substance is not known 
(e.g. amphetamines or MDMA and derivates), the generic 
category (e.g. stimulants (total)) should be recorded. 
Where prescribed drugs are mentioned, it is essential that 
psychological, social or medical problems are caused by 
the substance. 
Usual route of 
administration 
(primary drug) 
1. Inject 
2. Smoke/inhale 
3. Eat/drink 
4. Sniff 
5. Others 
0.   Not known 
Injection of drugs represents a primary form of risk 
behaviour for drug users It is of particular importance with 
regard to infectious diseases (hepatitis, HIV) as well as 
other diseases and injuries, and the reduction of injecting 
behaviour is the aim of many harm reduction 
programmes. The ‘usual route of administration’ refers to 
the route of administration of the primary drug. 
Ever 
injected/currently 
(last 30 days) 
inject 
1. Ever injected, but not currently 
2. Currently inject 
3. Never injected 
0. Not known 
Here injection behaviour with regard to all drugs has to be 
taken into account, regardless of whether the drugs are 
primary or secondary drugs. This item and item number 
16 in the TDI Protocol ver.2.0 identify the injection of 
drugs other than the main drug and thus give a good 
indication of risk behaviour. This is of particular 
importance with regard to the transmission of infectious 
diseases (hepatitis, HIV) as well as other diseases and 
injuries, and issues of harm reduction. Injection for 
medical purposes should be excluded (diabetes, etc.). 
‘Currently injected’ refers to whether a client has injected 
any drug at least once in the past 30 days. The reference 
point for the 30-day period of use is the start of treatment, 
i.e. the first face-to-face session. 
 
